A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Trial Profile

A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Levofloxacin
  • Indications Gram-negative infections; Pseudomonal infections; Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPECT-cUTI
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2016 Results of two studies (ASPECT-cIAI and ASPECT-cUTI) published in the Journal of Antimicrobial Chemotherapy
    • 05 Oct 2016 Results of pooled analysis of this and two other phase 3 trials published in the Journal of Antimicrobial Chemotherapy (2016).
    • 15 Jun 2016 Analysis of diabetes patients in this and two other trials (see profile 198179 and 193698) will be presented at the American Society for Microbiology's ASM Microbe 2016 meeting, according to a Merck & Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top